Discover how an innovative blood test can help optimize the clinical management of HPV-driven OPSCC

Join us at the virtual American Head & Neck Society (AHNS)
10th International Conference on Head and Neck Cancer to learn about
NavDx® – the first and only clinically validated circulating
tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the
optimal clinical management of HPV-driven cancer across the care continuum.1

Visit the Naveris booth through
the AHNS meeting app, or at

To learn more, we invite you to attend our live-streaming symposium,
Detection of HPV-Driven Oropharyngeal Squamous Cell Carcinoma:
Clinical Evidence of an Innovative Blood Test and
Implications for Multidisciplinary Management

Dr. Eric Genden, ENT Surgeon at Mount Sinai Hospital
Dr. Glenn Hanna, Oncologist at Dana-Farber Cancer Institute

Sunday July 25, 11:30am – 12:30pm CDT

We look forward to your visit!

Reference: 1. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol. 2020;38(10):1050-1058.